Nodenza Venture Partners launched - focus on international early-stage and pre-commercial biotech & medtech opportunities
16 oct. 2024 07h00 HE
|
Nodenza Venture Partners
Nodenza Venture Partners launched Focus on international early-stage and pre-commercial biotech & medtech opportunities New York, October 16, 2024 – Nodenza Venture Partners (“Nodenza”) has been...
Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
15 oct. 2024 16h15 HE
|
Upstream Bio
Upstream closes $293 million upsized IPO including full exercise of underwriters’ option to purchase additional shares
4VITAHEALTH™ Launches Groundbreaking Mental Health Supplements
15 oct. 2024 08h00 HE
|
4VITAHEALTH
4VITAHEALTH Launches Groundbreaking Mental Health Supplements
Attovia Therapeutics Appoints Chief Financial Officer
15 oct. 2024 07h30 HE
|
Attovia Therapeutics, Inc.
FREMONT, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics announced the appointment of Steven Chan as Chief Financial Officer. Mr. Chan brings extensive financial strategy and...
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024
15 oct. 2024 07h30 HE
|
Tourmaline Bio, Inc.
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November
Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors.
15 oct. 2024 07h30 HE
|
Molecure
This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as...
Allyx Therapeutics Awarded $3.3 Million NIH Grant to Support Further Clinical Studies of Lead Candidate ALX-001
15 oct. 2024 07h05 HE
|
Allyx Therapeutics Inc.
Allyx Therapeutics has been awarded a $3.3 million grant as part of the NIH's Small Business Innovation Research Commercial Readiness Pilot program
Forbion raises in excess of €2 billion for two new funds
15 oct. 2024 01h00 HE
|
Forbion
Forbion’s largest fundraising to date with Forbion’s Growth Opportunities Fund III raising €1.2 billion & Forbion Ventures Fund VII raising €890 million
Inventiva annonce un financement allant jusqu’à 348 millions d'euros afin d’avancer l’étude NATiV3 de Phase 3 dans la MASH
14 oct. 2024 02h30 HE
|
INVENTIVA
► Inventiva obtient 94,1 millions d’euros dans le cadre d’un financement en plusieurs tranches d'un montant maximum de 348 millions d'euros, sous réserve de la réalisation de certaines conditions,...
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
14 oct. 2024 02h30 HE
|
INVENTIVA
Inventiva secures €94.1 million of a multi-tranche equity financing of up to €348 million, subject to satisfaction of specified conditions, from both new and existing investors, and up to $30 million...